Wegovy side effects

Quick Answer

The most common side effect of Wegovy is nausea, which hits roughly 25% to 44% of people in clinical trials. Diarrhea, vomiting, constipation, abdominal pain, bloating, belching, headache, and fatigue each affect at least 5% of users. Symptoms usually peak during dose increases and often fade.

The FDA’s strongest warning — a boxed warning — flags a risk of thyroid C-cell tumors based on rodent studies, though it’s unknown whether that applies to humans. Other serious but uncommon events include pancreatitis, gallbladder disease, acute kidney injury from severe dehydration, and slowed stomach emptying severe enough to cause a blockage. In a large cardiovascular outcomes trial, about 16% of people stopped Wegovy because of side effects, versus 8% on placebo. For a deeper look at the full safety picture, see our side effects overview.

This article is for general education only and does not replace medical advice from a licensed healthcare professional.

Here’s what the clinical evidence actually says — no panic, no hype.

How Wegovy Works — and Why Side Effects Happen

Wegovy’s active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. Semaglutide mimics it: it slows stomach emptying, helps the pancreas release insulin after meals, and tells your brain you’re full sooner.

The stomach-slowing effect directly causes the nausea, bloating, and belching. Food hangs around longer, so even a small meal can feel uncomfortable. The appetite suppression in the brain drives weight loss; the slowed gastric emptying makes the side effects so predictably gastrointestinal.

Injection, Pill, and Higher-Dose Options: Do They Change Side Effects?

Wegovy comes as a once-weekly injection, a once-daily pill, and a higher-dose injection for people who’ve already tolerated the standard maintenance dose. Because all three use the same active ingredient, the core side-effect profile — gastrointestinal discomfort — is similar.

The injection uses a gradual dose-escalation schedule designed to help the stomach adapt, which is why nausea often fades after the first few weeks. The pill also starts low and increases gradually to a full maintenance level. The pill has strict administration requirements: it must be taken on an empty stomach with a specific waiting period before any food or drink. Always follow your prescribing doctor’s instructions exactly. In its pivotal trial, the pill produced the same list of GI complaints as the injection — nausea, diarrhea, vomiting, constipation, and stomach pain.

The higher-dose injectable option is for people who’ve already tolerated the standard maintenance dose. Because it pushes the dose further, there’s a possibility of more intense GI side effects, though long-term safety data for that strength are still emerging.

Missing doses for more than two weeks can affect tolerability; your doctor can advise whether a dose adjustment is needed.

Common vs. Serious: What the Clinical Trials Actually Found

The STEP clinical program and the massive SELECT trial — 17,604 people followed for an average of 39.8 months — give the clearest picture we have.

Nausea was the standout complaint, typically mild to moderate and improving over time. In SELECT, 16% stopped semaglutide because of side effects versus 8% on placebo. That gap shows tolerability isn’t universal: while many push through, a significant minority cannot.

Other frequent issues included diarrhea, constipation, vomiting, abdominal pain, bloating, belching, heartburn, dizziness, and fatigue. Injection site reactions — redness, itching, mild swelling — were uncommon (1.4% to 2.4%). Hair loss was reported in roughly 3% on Wegovy versus 1% on placebo (more on this below).

Serious safety signals are rarer, but documented. Real-world data from a 2023 JAMA study found roughly 5 cases of pancreatitis per 1,000 person-years of semaglutide use. A 2025 meta-analysis linked semaglutide to a slightly higher rate of gallbladder disease — about a 1.2-fold increase. The FDA strengthened warnings in late 2024 to include gastroparesis (stomach paralysis) and intestinal blockage. They’re uncommon, but not negligible, especially if you already have underlying gut motility issues.

Other serious warnings: acute kidney injury from severe dehydration (vomiting or diarrhea), severe allergic reactions, and, for people with type 2 diabetes, hypoglycemia when Wegovy is combined with insulin or sulfonylureas. People with diabetes and existing diabetic retinopathy may also experience a worsening of that condition, so routine eye exams are part of the prescribing information recommendations.

One warning disappeared: suicidal ideation had been listed as a potential risk, but in January 2026 the FDA removed it after an extensive review found insufficient evidence of a causal link.

No published studies track side effects beyond about 3.3 years, so longer-term safety remains unknown.

Side Effects to Discuss With Your Doctor

Some side effects warrant an urgent medical conversation. Contact your doctor if you experience:

Because Wegovy slows stomach emptying, food can sit in the stomach longer than expected, raising the risk of aspiration during sedation — tell your anesthesiologist if you have surgery scheduled.

For women of childbearing age: semaglutide can restore fertility when obesity has disrupted ovulation. The drug is contraindicated during pregnancy, and guidelines recommend stopping Wegovy at least two months before a planned pregnancy. Because unplanned pregnancies have been reported, people who could become pregnant may want to discuss contraceptive options with their healthcare provider.

What the Internet Often Gets Wrong About Wegovy Side Effects

Confusing Wegovy with Ozempic or generic “semaglutide”

Ozempic is the same molecule but approved for type 2 diabetes, with a different dose range. Rybelsus is an oral semaglutide for diabetes. Compounded semaglutide sold online is not FDA-approved and may contain forms of semaglutide not found in FDA-approved products. If a side-effect horror story doesn’t specify which version or supplier, you can’t safely generalize.

Panic over hair loss without context

The 3% incidence is real. But the most plausible explanation is telogen effluvium — temporary shedding triggered by the physiological stress of rapid weight loss, not a permanent toxic effect. A 2025 University of British Columbia pre-print study suggested the risk may be higher for women. Hair typically regrows once weight stabilizes and nutritional status improves.

Treating “Ozempic face” as a medical side effect

The hollowed appearance some people develop after dramatic weight loss is facial fat loss, a consequence of losing a large amount of weight quickly — regardless of how you lose it. Calling it a drug side effect is misleading.

Assuming rodent thyroid tumors predict human cancer

Rodents have dense GLP-1 receptors on thyroid C-cells; humans have very few. The FDA label states explicitly: “It is not known if Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.” People with a personal or family history of medullary thyroid cancer or MEN 2 should not take Wegovy. For everyone else, the actual risk remains unknown.

Believing forum anecdotes are as valid as trial data

Online communities amplify rare events. A single post about gastroparesis can feel like an epidemic. The real rates of serious GI complications are low but not zero. Both the alarmist and the dismissive extremes miss the point.

Bottom Line

Forget the TikToks. You have a drug that reliably turns your stomach for a few weeks, occasionally triggers something worse, and needs a doctor’s hand on the wheel. Most people adjust, but 1 in 6 in the key trial stopped because of side effects. Serious risks like pancreatitis, gallbladder disease, and gastroparesis are real but rare. The largest unanswered questions — safety beyond about 3.3 years, and whether the rodent thyroid findings apply to people at all — remain. Decide based on the evidence, not the fear.

Frequently Asked Questions

What are the most common side effects of Wegovy? Nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, belching, headache, and fatigue. In clinical trials, nausea affected roughly 25% to 44% of people.

Is Wegovy linked to thyroid cancer? In rodent studies, semaglutide caused thyroid C-cell tumors. Whether that happens in humans is unknown. People with a personal or family history of medullary thyroid cancer or MEN 2 should not use Wegovy.

How long do Wegovy side effects last? GI symptoms usually peak during the first few weeks at a new dose and then fade. Some mild nausea or altered bowel habits can persist, but severe, ongoing symptoms warrant a discussion with your doctor. About 16% of users stop because of side effects.

Are side effects different for women and men? In the STEP trials, about 90% of women reported at least one side effect versus roughly 83% of men, and women were slightly more likely to discontinue. The types of side effects are largely the same. Women may be at higher risk for temporary hair shedding from rapid weight loss, and semaglutide can restore ovulation — so pregnancy status matters.

Does the Wegovy pill cause fewer side effects than the injection? No, the oral version produced a similar gastrointestinal side-effect profile in its pivotal trial. The pill’s strict dosing routine — empty stomach, strict waiting period — is essential for absorption but does not eliminate nausea or other GI issues.

What are the long-term side effects of Wegovy? The longest published data come from the SELECT trial, which followed people for about 3.3 years. Beyond that, safety is not yet established. Known serious risks that can appear over months include pancreatitis, gallbladder disease, and, rarely, severe stomach-emptying problems. Continuous monitoring is recommended.